Results 21 to 30 of about 19,767 (298)
Medicina, 2022 Prolactinomas are the commonest form of pituitary neuroendocrine tumor (PitNET), representing approximately half of such tumors. Dopamine agonists (DAs) have traditionally been the primary treatment for the majority of prolactinomas, with surgery ...
W. Inder, C. Jang
semanticscholar +1 more source
Prolactinoma: Clinical Characteristics, Management and Outcome
Cureus, 2022 Aim Prolactinoma, a prolactin (PRL) secreting functioning pituitary tumor, is the most common of all pituitary adenomas (PA) accounting for 40-60% and dopamine agonists (DA) are the cornerstone of treatment.
Hira Irfan +8 more
semanticscholar +1 more source
Arquivos Brasileiros de Endocrinologia & Metabologia, 2014 Os prolactinomas são os adenomas de hipófise mais comuns e frequentemente afetam mulheres jovens, em faixa etária de fertilidade. A hiperprolactinemia causa hipogonadismo, irregularidade menstrual ou amenorreia em mulheres, níveis baixos de testosterona sérica em homens e infertilidade e disfunção sexual em ambos os gêneros.
Glezer, Andrea, Bronstein, Marcello D.
openaire +4 more sources
Journal of Clinical Endocrinology and Metabolism, 2022 CONTEXT Dopamine agonist-induced (DA-induced) impulse control disorder (ICD) represents a group of behavioral disorders that are increasingly recognized in patients with prolactinoma.
S. Şahin +8 more
semanticscholar +1 more source
The SF3B1R625H mutation promotes prolactinoma tumor progression through aberrant splicing of DLG1
Journal of experimental & clinical cancer research : CR, 2021 Recently, a hotspot mutation in prolactinoma was observed in splicing factor 3b subunit 1 (SF3B1R625H), but its functional effects and underlying molecular mechanisms remain largely unexplored.
Jing Guo +7 more
semanticscholar +1 more source
Scientific Reports, 2021 Prolactinomas represent the most common type of secretory pituitary neoplasms, with a therapeutic management that varies considerably based on tumour size and degree of hyperprolactinemia.
Bianca M. Leca +7 more
semanticscholar +1 more source
Aggressive prolactinoma (Review).
Experimental and Therapeutic Medicine, 2021 Aggressive prolactinoma (APRL) is a subgroup of aggressive pituitary tumors (accounting for 10% of all hypophyseal neoplasia) which are defined by: invasion based on radiological and/or histological features, a higher proliferation profile when compared ...
A. Valea +6 more
semanticscholar +1 more source
Interpretation of the 2022 ICCE/AME Position Statement for Clinical Practice in Pituitary Prolactinoma: Update on Clinical Characteristics and Points of Diagnosis and Treatment of Pituitary Prolactinoma [PDF]
Zhongguo quanke yixuePituitary prolactinoma is a neuroendocrine disease caused by excessive pituitary prolactin-cell adenoma synthesis and prolactin secretion. The standardized diagnosis and treatment of pituitary prolactinoma in of great significance for recovering and ...
TAN Huiwen, LI Danting, YU Yerong
doaj +1 more source
The pituitary TGFb1 system as a novel target for the treatment of resistant prolactinomas [PDF]
, 2016 Prolactinomas are the most frequently observed pituitary adenomas and most of themrespond well to conventional treatment with dopamine agonists (DAs).
Camilletti, María Andrea +3 more
core +2 more sources
Cure and Hormonal Control After Prolactinoma Resection: Case Series and Systematic Review
Journal of the Endocrine Society, 2021 Context Surgical management of prolactinomas is an important treatment for patients intolerant of dopamine agonist therapy. However, predictors of postoperative outcomes remain unclear.
Marisa C Penn +10 more
semanticscholar +1 more source